ClinicalTrials.gg
RecruitingNCT07151937Updated May 11, 2026

A Study of LAD191 in Adults With Hidradenitis Suppurativa

A Phase 2 interventional study of LAD191 and Placebo in Hidradenitis Suppurativa, sponsored by Almirall, S.A.. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Almirall, S.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 50 studies in Hidradenitis Suppurativa with a site in Spain — 9 open to participants now, 23 under way, 11 of them phase 3. Hidradenitis Suppurativa · Spain.

Planned enrollment
33rd of 45
200 · median 247
Started
2025
with 15 others
Phase 2
19 of 50
3 open now
Primary completion
2027-05
later than 10 of 22 live
Registered
43rd of 50
by date
Lead sponsor
1 of 50
Almirall, S.A.

Among the 50 studies in Hidradenitis Suppurativa with a site in Spain, this one is the 33rd largest by planned enrollment of the 45 interventional ones that give a count, is one of 16 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 10 of the 22 other live ones, and was the 43rd registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 50 studies in Hidradenitis Suppurativa with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 62 Hidradenitis Suppurativa studies recruiting now, 34 (55%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hidradenitis Suppurativa with a site in Spain, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.

Read the detailed description

The purpose of this study is to assess the multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS). The study has a prospectively defined adaptive design that will utilize interim data for futility evaluation.

The study includes up to 4 weeks screening period 16-week double-blind, placebo-controlled period (Treatment period 1), 16-weeks LAD191 double-blind period (Treatment period 2), and 12-week safety follow-up.

The study participants will be randomized to one of the following treatment arms: LAD191 dose A, LAD191 dose B; LAD191 dose C, Adalimumab or Placebo.

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged greater than or equal to (>=) 18 to less than or equal to (\<=) 65 years.
  • A diagnosis of moderate-to-severe HS defined as a total of >= 5 inflammatory lesions (i.e., number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline/Day 1 visits, with signs and symptoms of HS for at least 6 months.
  • HS lesions present in at least 2 distinct anatomic areas (e.g., left and right axilla), one of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline/Day 1 visits.
  • History of inadequate response, intolerance, or to a course of a systemic antibiotics for treatment of HS at the screening visit.
  • Regular use of over-the-counter topical antiseptics on HS lesions and agrees to regular use, throughout the entirety of the study.
  • Participants who are women of (WOBCP) and male participants must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD191 during the study.

Exclusion criteria

Exclusion Criteria:

  • HS with >20 draining tunnels at the Screening or Baseline/Day 1 visit.
  • Ongoing medical conditions requiring systemic /immunomodulating treatments during the study.
  • Known to LAD191 or any of its .
  • Known hypersensitivity to adalimumab or biosimilar or any of its excipients or meeting any warning or to adalimumab treatment as per the approved product information, and as per the Investigator's judgment.
  • Hypersensitivity or systemic reaction to a prior biologic (antibody-based) therapy, regardless of indication, that was , as per the Investigator's judgment.
  • Prior treatment with LAD191.
  • Live or attenuated vaccinations 4 weeks prior to Baseline/Day 1 or is planning to receive any such vaccine during the study.
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
  • Intention to use any concomitant medication or therapy that is not permitted by this protocol or failure to meet the required for a particular prohibited medication prior to Baseline/Day 1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    LAD191 Dose A

    Participants will receive dose A LAD191 subcutaneous (SC) injection during both Treatment Period 1 and Treatment Period 2, unless if Dose A is eliminated after interim analysis, participants will receive the highest available dose of LAD191 during Treatment Period 2.

    Drug: LAD191

  • Experimental
    LAD191 Dose B

    Participants will receive dose B LAD191 SC injection during both Treatment Period 1 and Treatment Period 2, unless if Dose B is eliminated after interim analysis, participants will receive the highest available dose of LAD191 during Treatment Period 2.

    Drug: LAD191

  • Experimental
    LAD191 Dose C

    Participants will receive dose C LAD191 SC injection during both Treatment Period 1 and Treatment Period 2, unless if Dose C is eliminated after interim analysis, participants will receive the highest available dose of LAD191 during Treatment Period 2.

    Drug: LAD191

  • Placebo comparator
    Placebo

    Participants will receive matching LAD191 placebo SC injection during Treatment Period 1 and will begin treatment with the highest available dose of LAD191 during Treatment Period 2.

    Drug: LAD191 · Other: Placebo

  • Active comparator
    Adalimumab

    Participants will receive adalimumab SC injection during Treatment Period 1 and will begin treatment with the highest available dose of LAD191 during Treatment Period 2.

    Drug: LAD191 · Drug: Adalimumab

Interventions

  • DrugLAD191

    LAD191 subcutaneous injection.

  • OtherPlacebo

    LAD191 Placebo subcutaneous injection.

  • Adalimumab subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving 50 Percent (%) Reduction from Baseline in Hidradenitis Suppurativa Clinical Response (HiSCR-50)

    HiSCR-50 is defined as ≥50% reduction in total AN count, with no increase in abscess count, and no increase in draining fistula count relative to baseline.

    Time frame: At Week 16

Secondary outcomes

  1. Proportion of Participants Achieving 75% Reduction from Baseline in HiSCR-75 at Week 16

    HiSCR-75 is defined as ≥75% reduction in total AN count, with no increase in abscess count, and no increase in draining fistula count relative to baseline.

    Time frame: At Week 16

  2. Proportion of Participants Achieving 90% Reduction from Baseline in HiSCR-90 at Week 16

    HiSCR-90 is defined as 90% reduction in total AN count, with no increase in abscess count, and no increase in draining fistula count relative to baseline.

    Time frame: At Week 16

  3. Proportion of Participants Achieving 55% Reduction from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4-55) at Week 16

    The IHS4 is determined by counting nodules, abscesses, and draining tunnels (fistulae/sinuses). IHS4 (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. A score of 3 or lower indicates a mild stage of hidradenitis suppurativa, a score of 4-10 indicates a moderate stage, and a score of 11 or higher indicates a severe stage of the disease. IHS4-55, is a dichotomous IHS4 variable based on a ≥55% reduction of the total score.

    Time frame: At Week 16

  4. Change from Baseline in Skin Pain Numerical Rating Scale (NRS) at Week 16

    Skin Pain NRS is an 11-point scale in which patients are asked to rate their skin pain over the prior 24 hours, where 0 is no skin pain and 10 is pain as bad.

    Time frame: At Week 16

  5. Change from Baseline in Hidradenitis Suppurativa Quality of Life (HiSQOL) at Week 16

    The HiSQOL was specifically developed for use in clinical trials to assess Quality of Life (QoL) and comprises a 17-item questionnaire grouped into 3 sub-scales covering symptoms, psychosocial, and activity-adaptation aspects, with a recall period of seven days. Each item is structured as a Likert-type scale with five or seven response levels and, for all items, the score ranges from 0 (not at all) to 4 (extremely). Individual item scores are summed and a total score ranging from 0 to 68 is calculated, where the higher the score the more impact HS has on quality of life.

    Time frame: At Week 16

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 45 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 18 months is above that.

Counting every sponsor, half of 55 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 3, 2025
StartActual
Nov 5, 2025
Primary completionEst.
May 25, 2027
CompletionEst.
Nov 25, 2027
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07151937
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Nov 5, 2025
Primary completion
May 25, 2027 (estimated)
Completion
Nov 25, 2027 (estimated)
Last update
May 11, 2026

Study contacts

Victor Castellano
Contact
gco@almirall.com
+34932746671
Estrella García
Contact
gco@almirall.com
+34620985953
Study Director
study director · Almirall, S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion